ArriVent BioPharma Inc. C... (AVBP)

18.54

-0.03 (-0.16%)

At close: Mar 28, 2025, 1:58 PM

ArriVent BioPharma Common Stock Cash Flow Statement

Table Mode

Year	FY24	FY23	FY22	FY21
Net Income	-80.49M	-69.33M	-36.91M	-51.61M
Depreciation & Amortization	n/a	n/a	n/a	n/a
Stock-Based Compensation	3.21M	895K	424K	66.67K
Other Working Capital	7.82M	11.22M	-9.95M	-4.23M
Other Non-Cash Items	n/a	n/a	-2.38M	42.67M
Deferred Income Tax	n/a	n/a	n/a	n/a
Change in Working Capital	7.07M	12.6M	-7.15M	-3.94M
Operating Cash Flow	-70.21M	-55.84M	-43.63M	-12.59M
Capital Expenditures	n/a	n/a	n/a	n/a
Acquisitions	n/a	n/a	n/a	n/a
Purchase of Investments	-194.16M	-25M	n/a	n/a
Sales Maturities Of Investments	1.7M	25M	n/a	n/a
Other Investing Acitivies	n/a	n/a	n/a	-40M
Investing Cash Flow	-192.47M	n/a	n/a	-40M
Debt Repayment	n/a	n/a	n/a	n/a
Common Stock Repurchased	n/a	n/a	n/a	n/a
Dividend Paid	n/a	n/a	n/a	n/a
Other Financial Acitivies	631K	44.92M	169.72M	119.82M
Financial Cash Flow	186.58M	42.86M	169.72M	89.87M
Net Cash Flow	-76.1M	-12.98M	126.09M	37.28M
Free Cash Flow	-70.21M	-55.84M	-43.63M	-12.59M